Why are my antidepressants not working?

If you are taking an antidepressant exactly as prescribed and still feel stuck, you are not alone. Some people see little benefit. Others feel side effects long before any improvement. And many experience a mix of both: partial relief plus fatigue, nausea, sleep disruption, or emotional blunting.

There are many reasons this can happen. Pharmacogenetics (PGx), the study of how genetic variation influences medication response, is only one piece of the puzzle. But for certain antidepressants, it can be a very practical piece because it helps explain how your body may process a medication and, in some cases, how likely you are to have higher or lower drug exposure than expected.

What “not working” often means with antidepressants

People usually mean one or more of these:

• Little or no symptom improvement after an adequate trial
• Improvement that fades or never reaches meaningful relief
• Side effects that limit dose increases or lead to stopping early
• Unpredictable response even with consistent dosing

The big picture: genetics is not the only reason

Before zooming in on PGx, it helps to acknowledge common non-genetic factors that can make antidepressants seem ineffective:

• Time and dosing: many antidepressants require several weeks at an effective dose to evaluate benefit.
• Diagnosis mismatch: for example, symptoms driven by bipolar disorder, substance effects, untreated ADHD, or medical conditions can look like depression and respond differently.
• Drug interactions: other medications and substances can raise or lower antidepressant levels.
• Adherence and timing: missed doses, inconsistent timing, or stopping early due to side effects can prevent benefit.
• Comorbidities and stressors: sleep disorders, thyroid disease, chronic pain, trauma, ongoing stress, and psychotherapy access all affect outcomes.

PGx does not replace this clinical assessment. It can complement it by explaining why a “standard” dose may not behave like a standard dose in your body for certain medications.

How pharmacogenetics can affect antidepressants

Many antidepressants are processed by liver enzymes that vary by genetics. The best-established examples involve genes such as CYP2C19 and CYP2D6 (and, for some drugs, CYP2B6). These genes can influence whether you metabolize a drug more slowly or more quickly than expected, which can shift medication exposure and affect both efficacy and tolerability.

A simple way to think about it:

• If you metabolize a medication faster than expected, drug levels may be lower, which can contribute to reduced benefit at typical doses.
• If you metabolize a medication slower than expected, drug levels may be higher, which can increase side effects and make it hard to stay on the medication long enough or at a high enough dose to help.

PGx examples focused on antidepressants

Below are concrete examples where PGx can help explain either lack of benefit or side effects. These are not guarantees, but they are patterns supported by major pharmacogenetic guidance sources.

Example 1: Citalopram or escitalopram that does not help enough

Citalopram and escitalopram are influenced by CYP2C19. CPIC guidance recommends considering an antidepressant not predominantly metabolized by CYP2C19 for certain CYP2C19 phenotypes (including ultrarapid metabolizers), because altered metabolism can affect exposure and response.

How this can feel in real life:
You take a typical dose, stay consistent, and still feel like the medication never fully “kicks in,” or the response is weaker than expected.

Example 2: Citalopram side effects at low doses, or concern for QT risk

Citalopram is a good example of how PGx can relate to tolerability and safety. The FDA label for citalopram (Celexa) recommends limiting the maximum dose to 20 mg once daily in patients who are CYP2C19 poor metabolizers, because higher exposure is expected.

How this can feel in real life:
You experience side effects early, or your clinician is cautious about increasing dose due to risk considerations, which can limit the ability to reach a dose that is effective.

Example 3: Sertraline that causes more side effects than expected

For sertraline, CPIC guidance includes recommendations for CYP2C19 poor metabolizers, such as considering a reduced starting dose with careful titration, or choosing an alternative not predominantly metabolized by CYP2C19.

How this can feel in real life:
A medication that is “usually well tolerated” causes notable fatigue, gastrointestinal symptoms, or activation even at typical starting doses.

Example 4: Paroxetine that causes strong side effects or feels “too strong”

Paroxetine is strongly influenced by CYP2D6. CPIC guidance suggests that for CYP2D6 poor metabolizers, clinicians may consider a lower starting dose, slower titration, and lower maintenance dosing.

How this can feel in real life:
Side effects show up quickly, dose increases feel difficult, or you feel over-medicated at doses that help other people.

Example 5: Paroxetine that does not work well despite dose increases

On the other end of the spectrum, CPIC guidance recommends considering an alternative drug not predominantly metabolized by CYP2D6 for CYP2D6 ultrarapid metabolizers, since rapid metabolism can make it harder to achieve typical exposure.

How this can feel in real life:
You try dose adjustments, but benefit remains limited, and it seems like the medication never reaches a steady, effective response.

Example 6: Venlafaxine with an unexpected response pattern

Venlafaxine is metabolized by CYP2D6. CPIC guidance recommends considering an alternative antidepressant not predominantly metabolized by CYP2D6 for CYP2D6 poor metabolizers.

How this can feel in real life:
The medication seems to produce side effects without the expected benefit, or the response is different than anticipated based on the dose.

Example 7: Vortioxetine that causes side effects at usual doses, or requires extra caution

Vortioxetine (Trintellix) is another antidepressant where CYP2D6 can matter. CPIC guidance includes recommendations such as selecting an alternative for CYP2D6 ultrarapid metabolizers and dose adjustments or alternatives for CYP2D6 poor metabolizers.

The FDA label also notes a maximum recommended dose of 10 mg/day in known CYP2D6 poor metabolizers.

How this can feel in real life:
Dose increases are difficult due to tolerability, or you need a more conservative approach than expected.

Example 8: If you are on a tricyclic antidepressant (TCA)

Tricyclic antidepressants (such as amitriptyline and nortriptyline) can be particularly sensitive to metabolism differences because they have well-known concentration-related side effects. CPIC has a dedicated guideline for CYP2D6 and CYP2C19 and TCA dosing.

For example, CPIC guidance for amitriptyline discusses using an alternative drug for certain CYP2D6 and CYP2C19 phenotypes, and dose reductions in poor metabolizers when the drug is warranted.

How this can feel in real life:
Dry mouth, constipation, dizziness, sedation, or other anticholinergic effects appear early, or the medication feels difficult to tolerate at doses needed for benefit.

An important nuance: not every antidepressant has actionable PGx guidance

It is normal to assume every antidepressant has a clear gene-based answer. In reality, the strength of evidence varies by medication and gene.

For instance, CPIC notes that the current data do not support using the pharmacodynamic genes SLC6A4 and HTR2A to guide antidepressant prescribing, even though they have been studied.

And for some drugs, there may be no gene-based dosing recommendations at this time (for example, CPIC notes no CYP2D6-based dosing recommendation for duloxetine).

This is one reason PGx works best as a targeted tool: extremely helpful for certain gene-drug pairs, less informative for others.

How PGx results are typically used in care

When PGx is relevant, clinicians commonly use it to inform decisions such as:

• choosing an antidepressant that is less dependent on an enzyme that is predicted to be very fast or very slow
• adjusting the approach to starting dose and titration
• anticipating who may need closer monitoring for side effects or lack of benefit
• recognizing situations where a drug interaction may amplify a genetic effect

How Gene2Rx can help

Gene2Rx is designed to make PGx insights accessible and fast, especially for people who already have consumer genetic data. With Gene2Rx you can generate a pharmacogenetics report in under 1 minute after upload, with a Psychiatric Medications Pharmacogenetics Report for $25 covering 23 psychiatric medications including many antidepressants.

A quick, important note on test type

Gene2Rx reports are generated from uploaded direct-to-consumer genetic data and are not clinical reports. In practice, that means many people use Gene2Rx as a rapid starting point: a way to identify which antidepressants may have relevant PGx guidance, and what questions to bring to a clinician. For high-stakes decisions, confirmatory clinical testing and clinician oversight can be appropriate.

What to do next if antidepressants are not working

A practical next step is to bring a clear summary to your clinician:

• Which antidepressant(s) you tried, at what dose, and for how long
• What “not working” meant for you (no benefit vs side effects vs both)
• Any other medications and supplements (interactions matter)
• Any family history of unusual medication response
• Whether you have existing consumer DNA data that could be used for PGx screening

PGx will not explain every case of antidepressant nonresponse, but when it applies, it can reduce trial-and-error and help make the next step more informed.